Navigation Links
Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy
Date:5/17/2013

MIAMI, May 17, 2013 /PRNewswire/ -- Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy.  The data are being presented at the AntiEplileptic Drug and Device Trials (AED) Xll meeting by Dr. Steven Schachter , Harvard Medical School epileptologist and Chairman of Insero's Scientific Advisory Board.  In this study, INS001 appeared safe and well tolerated.

INS001 is a naturally occurring compound that has shown promising activity in multiple preclinical epilepsy models.  Insero researchers believe that INS001 exerts its anti-epileptic effects through a unique combination of mechanisms: it is both a potent acetylcholinesterase inhibitor and an NMDA-receptor antagonist.  The compound has previously demonstrated good safety and signs of therapeutic activity in a Phase II trial in Alzheimer's disease, as well as in preclinical models of multiple sclerosis and neuropathic pain.

The Phase I trial was a single-center, inpatient, open-label, rapid dose escalation study in patients with drug-resistant epilepsy.  INS001 was safe and well tolerated at doses expected to be therapeutic, and increased cardiac parasympathetic tone and electrical stability were observed.

Dr. Schachter noted, "The positive safety demonstrated in this first trial of INS001 in drug-resistant epilepsy is a step forward in the clinical development of this therapy as a potential new treatment option for patients with epilepsy whose seizures are inadequately treated today."

Insero expects to initiate a Phase II proof of principle trial in patients with drug-resistant epilepsy by early next year.

Epilepsy affects about three million people in the U.S. and over 50 million people
'/>"/>

SOURCE Insero Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013
2. Best Practices for Tracking Tissue in the Healthcare Supply Chain, Webinar Hosted by Xtalks
3. Cambrex To Present At UBS Global Healthcare Conference
4. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. ViroPharma To Participate In Two May Healthcare Investor Conferences
7. PrimeraDx Featured in the Goldman Sachs Healthcare Research Teams GS Emerging Healthcare Series
8. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
9. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
10. CellHealth Institute is Named 2013 Edison Award Winner
11. AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  The Companion Diagnostics ... understanding and unprecedented access to the partnering deals ... healthcare companies during 2014. Using these ... into the partnering activities of the past year. ... the partnering and alliances deals announced worldwide.The initial ...
(Date:5/27/2015)... 27, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... has commenced a public offering of shares of ... its common stock and overallotment purchase rights to ... of common stock, warrants and overallotment purchase rights ...
(Date:5/27/2015)... , May 26, 2015 ... announced the addition of Jain PharmaBiotech,s new ... and Companies" to their offering. ... molecular diagnostics technologies that will play an ... health, pharmaceutical industry, forensics and biological warfare ...
(Date:5/27/2015)... , May 26, 2015 Research and ... the "Global Breast Cancer Monoclonal Antibodies Market ... Globally, Roche seems to dominate the breast ... Its block buster molecule, Herceptin has been able ... was found that breast cancer cells become recalcitrant ...
Breaking Biology Technology:Companion Diagnostics Deals and Alliances of 2014 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3
... July 26 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) will ... Thursday, August 5, 2010 at 4:30 p.m. Eastern time ... , , ... States ) or (707) 287-9361 (International). In addition, the call will be webcast ...
... and TORONTO , July 26 ... testing in clinical research and diagnostics, has acquired Xceed Molecular, ... Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The ... of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, ...
... SHANGHAI , July 23 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", ... probiotics products in China , today announced,it will host a conference ... 9, 2010 to discuss the fiscal year 2011 first quarter financial ... , , ...
Cached Biology Technology:Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine 2Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine 3Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine 4China-Biotics to Report Fiscal Year 2011 First Quarter Financial Results on August 9 2
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/26/2015)... May 26, 2015 Research ... addition of the "Saudi Arabia Biometric Systems ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric ... is projected to grow at over 22% ... is attributed to the surging demand for better ...
(Date:5/25/2015)... SYDNEY , May 25, 2015  Australia,s market ... inception stage, although 2014 saw the advent of several ... on 24 April 2015 is expected to ignite interest ... devices in Australia . This in ... the industry and drive new partnerships amongst vendors and ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4
... BioMed Central and Wilfrid Laurier University today announce ... that provides a visible point of open access ... the University community. Built on BioMed ... extensive open access knowledge and technology experience, Laurier ...
... the mice the researchers found alterations which may be closely ... of an international study led by the Leipzig Max Planck ... the current issue of the renowned journal Cell . ... Mnchen have generated and analyzed a mouse model in which ...
... Technology, an award-winning biometric technology research and development ... leader in workforce management solutions, has chosen M2SYS ... solution that seamlessly interfaces with Kronos time and ... fingerprint and finger vein identification, enabling Kronos customers ...
Cached Biology News:'Canadian excellence' strengthened by extensive adoption of open access 2Mouse model provides clues to human language development 2M2SYS Technology to Offer Desktop Biometric Technology to Kronos Customers 2
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Biology Products: